1332 ET - The European Commission approved Eisai and Biogen's drug Leqembi to treat certain patients with early stage Alzheimer's disease in the European Union. However, TD Cowen analysts say in a research note that it's unlikely the new approval will have a material effect on Biogen's books. "We suspect that the EU launch is likely to be slow and to be impeded by many of the logistical challenges that have impacted the U.S. launch," they write. As a result, they are not making changes to estimates.(connor.hart@wsj.com)
(END) Dow Jones Newswires
April 16, 2025 13:33 ET (17:33 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.